vivo 5'-deiodination of T4 proceeds via a PTU-insensitive pathway in the central nervous system and pituitary, while this pathway is not quantitatively important in the L. This mechanism accounts for the "locally generated" T3 in central nervous system and pituitary and could also provide the approximately one-third of extrathyroidally produced T3 not blocked by PTU administration in athyreotic T4-replaced rat. I Abbreviations used in this paper: Cm, cerebellum; Cx, cerebral cortex; DTT, dithiothreitol; IOP, iopanoic acid; L, liver; MMI, methimazole; N/P ratio, nuclear to plasma ratio; N['25I]T3, nuclear['25I]T3; P, anterior pituitary; PTU, propylthiouracil; rT3, reverse T3; T3, triiodothyronine; T4, thyroxine. 1176 J. Clin. Invest.
A B S T R A C T Propylthiouracil (PTU) is a well known inhibitor of thyroxine (T4) to triiodothyronine (T3) conversion as evidenced by its effect in several in vitro systems and by the decrease in serum T3 caused by this drug in either rats or man receiving T4 replacement. However, the failure of PTU to decrease the intrapituitary T3 concentration and to completely blunt the serum T3 concentration in T4-replaced athyreotic rats suggest that there may be a PTU-insensitive pathway of T4 to T3 conversion in some tissues. To address this question, we have studied the in vivo effect of PTU treatment on the generation of [125I]T3 from [1251]T4 in the serum and cerebral cortex (Cx), cerebellum (Cm), liver (L), and anterior pituitary (P) of euthyroid rats. Whereas PTU decreased the concentration of [1251I]T3 in the serum, L homogenates, and L nuclei after [1251]T4, it did not affect the concentration of [1251]T3 in homogenates or nuclei of Cx, Cm, or P. lopanoic acid pretreatment significantly reduced the ['251I]T3 concentration in serum, homogenates, and cell nuclei of all these organs. Neither agent affected the metabolism or tissue distribution of simultaneously injected ['31I]T3. The presence of PTU in these tissues was evaluated by in vitro assessment of iodothyronine 5'-deiodinating activity using both '251I]rT3 and [1251I]T4 as substrates. In agreement with the in vivo findings, generation of [1251]T3 from T4 in vitro was not affected by PTU in Cx, Cm, P but it was inhibited by 76% in L. However, rT3 5'-deiodination, known to be sensitive to PTU in these tissues, was inhibited in all four indicating that the PTU given in vivo was present in significant amounts. These results demonstrate that in rat Cx, Cm, and P unlike liver, PTU does not inhibit T4 to T3 conversion in vivo despite the presence of the drug in the tissues in amounts that significantly inhibit reverse T3 5'-deiodination. These results show that in INTRODUCTION 3,5,3'-Triiodothyronine (T3)' appears to be the major active thyroid hormone at the cellular level (1) . Studies in man and in rat indicate that more than two-thirds of extrathyroidal triiodothyronine (T3) is produced via 5'-deiodination of thyroxine (T4), a reaction which occurs in many tissues (2) . In some (liver, kidney, and heart), the bulk of intracellular T3 exchanges rapidly with plasma (3, 4) . However, in the pituitary, the T3 produced from T4 does not immediately equilibrate with the plasma T3 (2) . Furthermore, this locally produced T3 makes a contribution of 50% or more to the intracellular T3 in this tissue (2, 5) . T4 to T3 conversion, at rates sufficiently rapid to make a significant contribution to total intracellular T3, has been recently identified in the rat central nervous system (6) (7) (8) . Similarly this locally generated T3 does not readily exchange with serum T3. Furthermore, whereas hypothyroidism increases the T4 5'-deiodination in the pituitary (9) and brain (10) , this condition decreases the activity of this process in the liver (9) . The reason for this difference between various organs is not apparent and could reflect intrinsic differences in the pathways of T3 generation.
A number of studies on the effect of propylthiouracil (PTU) on T4 to T3 conversion are compatible with the idea that there may be more than one enzymatic pathway of extrathyroidal T3 generation. Thus, this agent does not cause >70% inhibition of serum T3 generation in in vivo studies in thyroidectomized, T4-replaced rats (11) (12) (13) (14) despite the fact that T4 to T3 conversion is inhibited over 90% in liver and kidney homogenates from PTU-treated rats (15, 16) . On the other hand, in the anterior pituitary, the generation of intracellular T3 in vivo is not inhibited by PTU (17) nor is T4 to T3 conversion affected in vitro by this agent (9, 18) . These results could be explained by a PTU-insensitive pathway for T3 production in anterior pituitary. Alternatively, recent studies in GH-3 cells raise the possibility that PTU may not enter some cells in effective concentrations (19) . Recent studies have shown that 5'deiodination of reverse T3 (rT3) in cerebral cortex may proceed by two different mechanisms, one of which is insensitive to PTU and has a lower Km for rT3 than the classical PTU-sensitive pathway (20) . Nanomolar concentrations of T4 inhibit only the PTU-sensitive reaction. Taken together, these data raise the possibility that a significant fraction of extrathyroidal T4 to T3 conversion may proceed via a process that is PTU insensitive. This pathway may be predominant in some tissues like the central nervous system and pituitary, but because of their small size and the incomplete exchange of intracellular T3 in these tissues with serum T3, the contribution of this source of T3 to the total extrathyroidal T3 pool may have been underestimated (2) . The physiological importance of such a source of T3 is difficult to approach in vitro, since these studies involve alteration of tissue structure by homogenization, addition of artificial cofactors, nonspecific binding of substrates to tissue proteins, etcetera. In addition, since one of the enzyme pathways may have a lower Km than the other (20) , one should use the appropriate endogenous concentration of T4 for each tissue to determine what fraction of the substrate is metabolized by each enzymatic pathway. Accordingly, we have chosen to study these questions in vivo by evaluating the effect of PTU on the generation of ['25I]T3 from ['25I]T4 in cerebral cortex (Cx), cerebellum (Cm), anterior pituitary (P), and liver (L). The results show that virtually all the [1251]T3 found in the nuclei of Cx, Cm, and P is PTU insensitive, whereas serum as well as L ['25I]T3 was significantly decreased by PTU pretreatment. PTU was present in significant amounts in all tissues examined.
METHODS
In vivo studies. Euthyroid male Sprague-Dawley rats weighing 175-250 g were obtained from Zivic-Miller, Allison Park, PA. The isotopic methods to study the sources of T3 in different tissues in vivo have been published (5, 6, 17, 21) . ['25I]T4 is injected intravenously with or followed by ['-3I]T3. The latter is used to calculate the contribution of plasma T3 to intracellular T3 as well as being recovery standard in the various extraction procedures. Knowing the concentration of ['31I]T3 in the plasma and in the tissues, and the ['"IIT3 in plasma, the ['25I]T3 found in a given tissue that is due to plasma [(25I]T3 can be calculated. The tissue ['25IJT3 in excess of that derived from plasma is that generated locally in the tissue (T3 [T4J).
In the present experiments, [1251I]T4, -100 jsCi/100 g body wt (4, 200 uCi/Mg sp act), and ['31I]T3, -10 uCi/100 g body wt (2,800 gCi/Pg sp act), were injected intravenously simultaneously 3 or 18 h before killing the rats (7) . Tracers were dissolved in 0.1-0.2 ml of 10% normal rat serum in isotonic saline containing 100-150 ,ug Nal to prevent the recirculation of radioactive iodine. Experiments performed 18 h after injecting ['251]T4 (Table I) (4-7, 17, 21) . At 18 h the N T3 [T4] is equilibrated with plasma [251I]T4 in all tissues examined (5, 7) . However, the nuclear to plasma (N/ P) ratio for ['31I]T3 present 18 h after T3 injection is greater than that at the time of equilibrium (tm) in these tissues. This is due to the more rapid decrease in plasma than tissue tracer T3 as we have previously discussed (5) . Therefore, the observed N/P ratio for ['31IJT3 at 18 h must be corrected to obtain the equilibrium N/P ratio for each tissue. The necessary correction factors have been determined in parallel experiments and were 0.52, 0.59, and 0.46 for Cx, Cm (7) , and for L, respectively. The corrected N/P ratios were multiplied by the observed plasma [1251]T3 to compute the tissue [125I]T3 derived from plasma (Table I ). These correction factors allow use of the same rats for analyses of different tissues and avoid the physiological perturbations associated with a second injection of ['31I]T3. For time intervals within a few hours of the t. for T3 for L, Cx and Cm, differences between the observed N/P and that present at the t. are not experimentally demonstrable (4, 5, 7) . Therefore, no corrections are required when both isotopes were given within 3 h of tissue analyses (Tables II and III). lopanoic acid (IOP, Telepaque R) was supplied by Mr. A. E. Soria, Winthrop Laboratories Co., New York. This was dissolved in alkalinized isotonic saline and 5 mg/100 g body wt were given intraperitoneally at various intervals before sacrifice. PTU was similarly dissolved and injected intraperitoneally at a dose of 1 mg/100 g body wt at indicated times. Control animals received the same vehicle with identical timing. The animals were killed by aortic exsanguination under light ether anesthesia and perfused with 30 ml of cold isotonic saline through the inferior vena cava, to minimize the contribution of trapped plasma to the tissue radioactivity (22) . Cell nuclei from Cx, Cm, P, and L were prepared as previously described (6, 22) . Identification and quantitation of ['31 ]T3 and ['25I]T3, and ['251IT4 bound to nuclei and present in tissue homogenates were also performed as described earlier (17, 22) . When ['31I]T3 in a given sample was present alone, i.e., in isolated nuclei or in serum from which all non-T3 '3'I was eliminated by affinity chromatography (23) , it was used to correct for the losses of ['251I]T3 during paper chromatography. Sufficient counts were accumulated to reduce counting error to <5%. Serum ['251I]T3 and ['31I]T3 were isolated by affinity chromatography followed by paper chromatography (5, 23) .
Pathways for In Vivo T4 5'-Deiodination
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In vitro studies Tissue preparation. 5'-Deiodinating activity was measured in homogenates of L, Cx, and P and in Cx microsomes. Tissues were homogenized in 5 vol (wt/vol) of a solution containing 0.32 M sucrose, 10 mM HEPES pH 7.0, and either 10 mM (P, Cx) or 1 mM (L) dithiothreitol (DTT), unless otherwise indicated. To prevent any effect of PTU contaminating the tissue on the enzyme during homogenization, we added 5 mM methimazole (MMI) to this buffer (24) . Microsomes of Cx were the 10,000-100,000 g pellet. MMI concentrations in the final homogenates were reduced by dilution to <0.6 mM. The final wash of the microsomal pellet did not contain MMI.
Deiodination assays. 5'-Deiodination of iodothyronines was measured in a total volume of 100 ,ul of reaction mixture containing 0.1 M potassium phosphate buffer (pH 7.0) 1 mM EDTA, 1-20 mM DTT, as indicated, and either [12511T4 or [5'-'25I] rT3. The concentrations of iodothyronines in each assay are specified in the Results. Reactions were started by adding tissue (70-150 Ag protein in 40-50 ul) and incubating at 370C under nitrogen. Incubation times and protein concentrations were designed to keep the fraction of substrate consumed to <20%. Reactions were terminated by addition of 50 ul serum followed by 350 ul ice-cold 10% TCA (rT3 assay) and by cold 95% ethanol containing 0.2 mg T4 and T3/ml and 1 mM MMI (T4 to T3 conversion assay) (15, 16) . 125I released from rT3 was quantitated by column chromatography (25) . Samples of the rT3 deiodination products under various assay conditions showed that the 125I/3' 1251-T2 ratio was 1.0. ['251]T3 formation was quantitated by paper chromatography (16) .
Reagents.
['25JIT4 and ['31IT3 were prepared by chloramine-T iodination and purified by paper chromatography (5 concentrations also were not different in controls and PTU-treated animals (data not shown). In two parallel experiments, where tracers were not given, there was no significant change in the serum T4 concentration (radioimmunoassay) with this regimen of PTU administration; in only one of these there was a slight fall in serum T3 (radioimmunoassay) of 0.17±0.09 ng/ml (P < 0.01).
RESULTS
Since IOP is a potent inhibitor of T4 to T3 conversion known to affect the pituitary and Cx T3 [T4] in vivo, we performed further experiments comparing its effect with that of PTU. Although the equilibration of N[251I]T3 with serum [251I]T4 is slow, both in central nervous system tissue and in pituitary, accumulation of ['25I]T3 is significant at 3 h and at this time the effect 1178 of IOP is also evident. Accordingly, the following experiments were done 3 h after the injection of ['251]T4. (Table III) .
The small amount of tissue precluded such comparisons in the pituitary where only the nuclear data were available. PTU did not affect the T3/T4 ratio in Cx, Cm, and pituitary but did cause a significant reduction of this ratio in the liver. In contrast, the ratio was lower in all four tissues in IOP-treated rats. These results are quite consistent with those that would be predicted from the effects of these agents on N['25I]T3 in Table TI .
Iodothyronine 5'-deiodinase activity in tissues from animals treated with PTU and IOP. The assays of iodothyronine 5'-deiodinase activity in microsomes from Cx are shown in Fig. 1 . PTU pretreatment did not affect T4 to T3 conversion while in IOP-treated rats there was a 70% decrease in this reaction rate. The lack of effect of PTU on T4 to T3 conversion in the Cx microsomes either in vivo or in vitro could be due to the failure of the drug to penetrate the central nervous system in adequate amounts. Since rT3 5'-deiodination in the euthyroid Cx microsomes is inhibited by PTU 50% in the PTU-treated rats. That PTU is an effective (20) , rT3 deiodination rates can be used as a "bioassay" inhibitor of rT3 deiodination in this tissue is evident of tissue PTU concentrations. Fig. 1 shows that the from the significant decrease in rT3 deiodinase activity total rT3 5'-deiodination rate is reduced by more than found in microsomes from all three groups in the pres- (Fig. 1) . This procedure reduced the activity in PTU-treated animals to levels identical to those found in control tissue, implying that the difference in total activities between control and in vivo PTU-treated rats was due to the presence of this drug in the tissue. As expected, IOPtreated rats also showed an inhibition of rT3 5'-deiodinase activity. Table IV shows the results of experiments where the 5'-deiodinase activity was assayed in crude homogenates of Cx, pituitary, and liver from similarly treated animals. In experiment 1, T4 to T3 conversion was assayed at 2 nM T4 and 20 mM DTT in all tissues. In vivo treatment with PTU did not affect T4 to T3 conversion in Cx or pituitary while it decreased the activity by 75% in the liver. In a second experiment the T4 5'-deiodinase activity was also measured in the presence of PTU (1 mM) added in vitro. In this assay the liver activity was measured at 100 nM T4 and 1 mM DTT to optimize the conditions for demonstrating an effect of PTU. The results were comparable to those of experiment 1. Thus, while no inhibition was detected in Cx and pituitary, there was -90% inhibition in the liver. The addition of PTU in vitro did not inhibit the activity in Cx and pituitary homogenates, but caused a 90% inhibition in the livers from control animals. PTU added in vitro did not further inhibit 5'deiodination of T4 in livers of PTU-treated rats.
In the first experiment, pretreatment with PTU caused a significant fall in the rate of 5'-deiodination of rT3 in both Cx (-40%, P < 0.005) and pituitary (30%, P < 0.05), which contrasts with the lack of effect of this treatment on the T4 to T3 conversion assay (Table IV ). In the liver the pretreatment with PTU induced a 95% fall in 5'-deiodination of rT3. Since the conditions of the assay in this experiment might have favored the effect of small amounts of PTU in the liver and partially overcome the effect of PTU in pituitary and Cx, a second experiment was carried out where the concentration of rT3 and DTT in the liver homogenates were the same as those used for the assay of the pituitary and Cx. In this case the liver was also homogenized in buffer containing 10 mM DTT as were the Cx and the pituitary. The inhibition observed in the liver and Cx of PTU-treated rats was entirely comparable to that of the first experiment. However, the rT3 5'-deiodination rates observed in the pituitaries in this experiment were not significantly different in the PTU-treated rats. Earlier studies have shown that 1 mM PTU gives maximal inhibition of PTU-sensitive rT3 5'-deiodination in rat Cx (20) . The data from the control rats in Table IV show that this amount of PTU causes only 50-70% inhibition of rT3 5'-deiodination in Cx and pituitary but 90% or greater inhibition in the liver. Since the in vivo PTU treatment caused at least 60% inhibition of the PTU-sensitive fraction of rT3 5'-deiodinase, it suggests that roughly comparable quantities of PTU were present in all three tissues.
DISCUSSION
The enzyme converting T4 to T3 in the central nervous system is critically important to the thyroid status of this tissue since recent studies in euthyroid rats indicate that locally generated T3 accounts for >70% of the nuclear T3 in Cx and 50% of that in Cm (6, 7) . In that respect, the tissue resembles the rat anterior pituitary in which 50% of the nuclear T3 is derived from local T4 to T3 conversion whereas <30% of nuclear T3 in rat liver and kidney is derived from this source (5) .
The present experiments show further similarities of central nervous system T4 to T3 conversion to that in anterior pituitary. Pretreatment of rats with amounts of PTU previously shown to inhibit extrathyroidal T3 production by 70% in T4-treated athyreotic rats (13, 14) had no effect on the local production of T3 from T4 in the Cx or Cm. Similar results have been observed in rat pitu'itary and are confirmed in this study (17) .
Though PTU and IOP both reduced the serum [125I]T3 present 3 h after ['25I]T4, the amount of T3 was differentially affected by the two agents in the various tissues. Whereas IOP decreased the concentration of [125I]T3 in all organs, PTU did so only in the liver. The fact that PTU decreased the T3/T4 ratio in the liver to the same extent as the tissue [1251]T3 (Table III) while in the other tissues this ratio did not change, indicates that the differences observed cannot be ascribed to differential effects of PTU on the tissue uptake of ['251]T4. Likewise, the fact that the ['31I]T3 concentration was not decreased by either PTU or IOP in tissues or serum indicates that the differences cannot be explained by differential effects of PTU on T3 metabolism or distribution. Taken together, these findings point to a difference in the sensitivity to PTU of the process responsible for the generation of T3 in these tissues.
In agreement with in vivo data, T4 to T3 conversion was not affected when assayed in vitro in Cx microsomes from animals treated with PTU while it was decreased in about the same proportion as the [1251]T3 content in this tissue was decreased in vivo in rats that received IOP. There are two lines of evidence that indicate that PTU was present in Cx; the first is that when iodothyronine 5'-deiodinase was assayed by ['251I]rT3 deiodination there was a significant difference between controls and PTU-treated animals (Fig. 1B) . Second, when PTU was added to the reaction mixture, it induced a 70% fall in rT3 5'-deiodination in the Cx microsomes from controls while it only modestly de- 
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Cu0 40-0 I amount of PTU-insensitive activity was unaffected by PTU in vivo, suggesting that PTU was present in the tissue though at less than maximally inhibitory concentrations. Since PTU might have been present only in trapped plasma or in cells other than those possessing 5'-deiodinase activity and possibly artifactually affected deiodinase activity, tissues were homogenized and microsomes isolated in the presence of 5 mM MMI. This drug does not inhibit 5'-iodothyronine deiodinase but has been shown to prevent the effect of PTU, subsequently added, on kidney deiodinase (15) . The MMI was present throughout the preparation of the microsomes and removed in the final step before the assay. These observations, therefore, suggest that PTU was already bound to the enzyme in vivo.
Comparable results were observed in tissue homogenates (Table IV) all taken from the same animals. T4 to T3 conversion activity in the Cx and pituitary was not affected by PTU-pretreatment while it was reduced by 75% (first experiment) and 90% (second experiment) in the liver. In the first experiment the assay conditions (2 nM T4, 20 mM DTT) were the same in all three tissues. Accordingly, the differences in PTUsensitivity among tissues cannot be attributed to differences in the assay conditions. Again the presence of PTU in the Cx and pituitary was evidenced by the inhibition of rT3 5'-deiodination, although in pituitary this was not consistent. The addition of 1 mM PTU in vitro further inhibited the reaction in all three tissues from control animals. In PTU-treated rats, the additional inhibition caused by in vitro PTU relative to the basal activity (controls measured in the absence of PTU) was only modest indicating the presence of PTU in these tissues at significant, though submaximal, concentrations. Thus the differences between Cx, pituitary, and liver with respect of rT3 5'-deiodinase activity after in vivo PTU can be attributed to the fact that in liver, a higher fraction of this activity, if not all, is PTU sensitive. In the second experiment, shown in Table IV , the rT3 deiodination in liver was assayed under the same conditions as were the pituitary and the Cx (2 nM rT3 20 mM DTT) to eliminate the possibility that the different conditions used in the liver in experiment 1 could have favored the effect of PTU (more substrate, less cofactor, [15] ). The degree of inhibition was comparable to that observed in experiment 1.
Evidence for two pathways for rT3 5'-deiodination in Cx in vitro has been published recently (20) . One mechanism similar to that previously identified in liver (16) and kidney (15) , has a Km of 31 nM, is inhibited by PTU but little if at all by up to 1 AM T4. A second mechanism has a low Km for rT3 (2.7 nM) is insensitive to 1 mM PTU but is inhibited by low concentrations of T4 (Ki, half maximal inhibitory concentration for T4~-2 nM). The present results indicate that in vivo virtually all the local T3 production in Cx, Cm, and pituitary occurs by a PTU-insensitive mechanism. However, ['25I]T3 content in the liver is quite sensitive to PTU as reflected in the reduced ratio of ['25I]T3/ ['251]T4 in this organ. Although this may be due to a rapid equilibration of ['251]T3 formed via a PTU-insensitive pathway with serum [251I]T3, the in vitro findings (75-95% inhibition of T4 to T3 conversion by in vivo PTU and similar inhibition induced by in vitro added PTU) suggest that the low hepatic ['251]T3 content after injection of ['251]T4 in PTU-treated rats reflects the minor importance of the PTU-insensitive pathway in the liver.
There are several implications of these findings. Firstly, it is known that maximal doses of PTU can reduce the serum concentration of T3 in thyroidecmized T4-maintained euthyroid rats by only 70%. Since there is near maximal inhibition of 5'-deiodinase activity in the liver and kidney under these circumstances, it is reasonable to speculate that the PTU-nonsuppressible serum T3 in these conditions is generated via a pathway similar to that found in the central nervous system and pituitary. Secondly, in the Cx, Cm, and pituitary, T3 (T4) accounts for 50% or more of the tissue T3, while in the liver and kidney T3 (T4) is of much less importance (5, 7) . This seems to be more than a coincidence though our present ignorance about the precise nature of the mechanisms involved in T4 deiodination allows us only to call attention to it. Thirdly, since the PTU administration is more likely to affect those tissues like liver and kidney whose T3 content depends heavily on serum T3, while not affecting as markedly the concentration of T3 in tissues like pituitary and Cx (provided the serum T4 concentration is not reduced), it should be a useful tool to study the physiological relevance of these two sources of intracellular T3.
